MeSH tree: D23.529.850.212
For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study sponsored by Neurotech Pharmaceuticals ...
Aug 8, 2025
0
559
For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have been no FDA-approved (or other) treatments to slow or stop vision loss. That changed on March 6, 2025, ...
Jun 4, 2025
0
48
A research team has established an innovative intracranial pre-olivary pretectal nucleus (OPN) optic tract injury model (pre-OPN OTI), shedding light on crucial mechanisms of functional axonal rewiring following central nervous ...
Mar 28, 2025
0
27
